Sanofi Pasteur Acquires Rights to Novel Meningitis Vaccine
Posted on: Wednesday, 7 June 2006, 12:00 CDT
Sanofi Pasteur, the vaccines business of the Sanofi-Aventis Group, has agreed to acquire exclusive worldwide rights to Emergent BioSolutions' proprietary proteins and related technology for the development of a novel meningitis B vaccine.
Under the terms of the agreement, the two companies will jointly evaluate and develop a pool of Emergent BioSolution's proprietary antigens as the basis of a multivalent subunit vaccine against Neisseria meningitidis infection.
Emergent BioSolutions identified these protein candidates using its patented Signature-Tagged Mutagenesis (STM) functional genomics technology in combination with functional proteomics techniques.
Emergent BioSolutions will have primary responsibility for product development activities through phase I clinical trials. Sanofi Pasteur will have primary responsibility for product development activities from initiation of phase II studies through to regulatory approval, and for all commercialization activities including worldwide sales and marketing.
Sanofi Pasteur has already paid Emergent BioSolutions an upfront license fee of E3 million and agreement terms provide for additional payments, including significant milestone payments along the development cycle and royalties on eventual products sales.
The companies are targeting a major unmet public health need as current vaccines do not provide protection against serogroup B meningitis.
Source: Datamonitor
Related Articles
- Emergent BioSolutions Signs Contract With BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine
- Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine
- Emergent BioSolutions Awarded Two Grants From NIAID to Support Development of the Company's Recombinant Botulinum Vaccine (rBOT) and Next Generation Anthrax Vaccine (NGAV) Candidates
- Emergent BioSolutions and University of Oxford Join Hands to Develop TB Vaccine
- Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vaccine With Funding From Wellcome Trust and Aeras Global TB Vaccine Foundation
- Emergent BioSolutions Announces Dr. Stephen Lockhart Joins Company to Lead Commercial Product Development Subsidiary
- Emergent BioSolutions Receives Development Contract From NIAID/BARDA to Fund Continued Development of Anthrax Therapeutic
- Emergent BioSolutions Reports Financial Results for 2006
- Emergent BioSolutions Remains Committed to Development of Enhanced Anthrax Countermeasures
- Emergent BioSolutions Signs Agreement With Sanofi Pasteur for Development of Novel Meningitis B Vaccine
 |
 |
User Comments (0)
RSS Feeds